Biotech Firm Propanc Secures $100M Digital Asset Funding for Cancer Treatment
Biotech Firm Propanc Secures $100M Digital Asset Funding for Cancer Treatment
Australian biotech company Propanc Biopharma has announced a strategic partnership with Hexstone Capital to raise up to $100 million. This significant funding initiative aims to establish a digital asset treasury, which will directly support Propanc's ongoing cancer treatment development program. The agreement begins with an immediate injection of $1 million, with Hexstone Capital retaining the option to contribute an additional $99 million, highlighting a growing trend of innovative financing in the medical sector through digital assets.
Propanc Biopharma said it has struck a deal to raise up to $100 million to build a digital asset treasury that will support its cancer-treatment program. Based on reports, the arrangement with Hexstone Capital begins with an initial injection of $1 million and gives the investor the option to provide as much as $99 million.